India: Bombay High Court Holds That Feranta Not Deceptively Similar To Intas Ferintas

Last Updated: 29 June 2017
Article by S.S. Rana & Co. Advocates

In a recent case filed by Ajanta Pharma Ltd (hereinafter referred to as the "Plaintiff") before the Bombay High Court (hereinafter referred to as the 'Court') seeking an injunction restraining Theon Pharmaceuticals (hereinafter referred to as 'Defendant No. 1') and Intas Pharmaceuticals (hereinafter referred to as 'Defendant No. 2') (collectively referred to as the Defendants) from infringing and passing off its mark "FERANTA", the Hon'ble Court vide order dated May 5, 2017 held that there was no prima facie case made out by the Plaintiff, and dismissed the present notice of motion filed by it against the Defendants.

Brief Facts:

The Plaintiff obtained for registration of the mark FERANTA under Application no. 1652066, on February11, 2008 in class 05 for pharmaceutical, medicinal and veterinary preparations. The Plaintiff has used the mark since 2013 for L-Methyfolate Calcium, Pyridoxal 5'- Phosphate, Methylcobalamin, Ferrous Ascorbate and Zinc Sulphate pharmaceutical tablets. The Plaintiff claims that it has had considerable sales of INR 88.21 lakhs (USD 136805 approx.) in 2015-16, and has run up promotional costs as well. The Plaintiff claims that in or around July, 2016, it discovered the Defendant No. 2's Ferrous Ascorbate and L-Methyl Folate tablet under the FERINTA mark (now abandoned), with a suffix 'XT', which was being sold as a dietary supplement. It further discovered that the Defendant No. 2 had applied for registration of its mark under application number 2969381, in the same class as that of the Plaintiff. The Registrar objected to the application, citing the Plaintiff's prior registration of FERANTA as a conflicting mark. On that objection, the Defendant No. 2 made another application on April 15, 2016 under no. 3235362 for the mark FERINTA XT. On August 11, 2016, the Hon'ble Court granted ex-parte ad interim injunction in favour of the Plaintiff directing the Defendant No. 2 to cease usage of FERINTA. On September 1, 2016, the Defendant No. 2 agreed to cease usage of FERINTA, and would instead use the mark INTAS' FERINTAS, with INTAS' set above the word FERINTAS, with the letter FER in black, and the rest in a rust red color and FERINTAS set in an oval lozenge device.

Defense taken by the Defendants:

  • That the Plaintiff has itself copied the trade mark from another party, and therefore cannot institute action against the Defendant No. 2.
  • That the Plaintiff's products are sold as pharmaceutical drugs, whereas the Defendant's products are sold as dietary supplements.
  • There is honesty in adoption of the trade mark, with FER- being derived from FERrous, and INTAS from the Company name.
  • That the present case does not fall under the ambit of Section 29 (1) but rather Section 29 (2) of the Trade Marks Act, 1999. The goods manufactured by the Plaintiff and the Defendant No. 2 cannot be conflated as Class 05 has a wide sweep, as if a party has only manufactured pharmaceutical drugs and not dietary supplements, there cannot be any likelihood of confusion. In other words, for a case falling under Section 29 (2) of the Trade Marks Act, 1999, mere similarity of marks is insufficient, and must be accompanied by a similarity or identity of goods; and even that will not completely fulfil the requirements of Section 29 (2), for a likelihood of confusion must be shown.

Plaintiff's Counter-Submissions:

  • That the Plaintiff has not copied anyone's mark, and the mark FERANTA lapsed in 1989 and was filed on a proposed to be used basis.
  • That the two products have precisely the same ingredients and serve exactly the same purpose. According to the Nice classification, pharmaceuticals include dietary and meal supplements and dietetic foods adapted for medicinal use (but, importantly, does not include meal supplements and dietetic foods not for medicinal use).
  • The contents or ingredients are the same, as are the trade and marketing channels and the consumer base. Any difference is formulation is trivial, as both products are vended to treat anemia.
  • The Plaintiff states that a party cannot slither around in Class 05 by saying its mark, though in that class, is for a different sub-class or sub-species. The test in law speaks to the existence of rival marks in a class, not in a sub-classification. A classification or sub-classification in any case is never as important as the manner of use. What the law prevents is a rival from adopting a deceptively similar mark.
  • That honesty in adoption is irrelevant, and in any case, there is no honesty on the part of the Defendant for adoption of the said mark, as the Defendant was well aware of the Plaintiff's prior registration and its mark inter alia from the Registrar's citing of the Plaintiff's mark as a conflicting mark.
  • The Plaintiff submits that the deconstruction of the mark into separate names and explaining how the trade mark is formed is wholly irrelevant to the present case.

Court's Observations:

  • The Court observes that the two marks have to be seen as a whole and not separately. Therefore, the Plaintiff's submission that the Defendant's mark should be considered without INTAS is dismissed. Furthermore, the Court held that looking at the two marks as a whole, there is no doubt that there is, in the words of the Supreme Court in JR Kapoor v Micronix India [1994 Supp (3) SCC 215] not the remotest chance of buyers and users being misguided or confused.
  • The Hon'ble Court observed that one must guard as much against an approach that is overbroad, and sweeps in all manner of goods easily distinguished, and one that is much too narrow. Given the similarity of marks, the next step would then be to test similarity of goods. The Defendant No. 2's product is not adapted for medical use. The Hon'ble Court further observed that the NICE classification (2016 version, 10th edition), in its entry for Class 5, says the class does not include meal replacements, dietetic food and beverages not for medical or veterinary use. If the Defendant No. 2's product is such a dietetic food, then that may be another point of distinction. The Hon'ble Court held that the two marks were sufficiently distinguishable.
  • The Hon'ble Court observed that the Defendant's products did not harm the public in general and did not warrant an injunction to preserve the public interest.
  • The Hon'ble Court also observed that there is a well-established sequence in which a claim in infringement and passing off (or either) should be examined. Though the causes of action are distinct, some of their tests overlap common to both is this sequencing:

    • Are the marks identical?
    • If not, are they similar;
    • What is the nature and degree of similarity;
    • What goods or services are they being used on or for?
    • Are those goods or services identical, or similar?

The Hon'ble Court stated that answers to these questions, in various permutations, yield a result. However, the Hon'ble Court stated that it is possible to invert this paradigm, and suggest that because the goods are either the same or similar, therefore one must work backwards to conclude that the marks must be similar, or held to be similar, and therefore, infringement and passing off must both be presumed. Identity or similarity of marks must be the first test, not the assumption, and we proceed to the goods or services from there, not the other way around.


"It is not possible to hold that a prima facie case is made out. The Motion fails. It is dismissed. There will be no order as to costs."

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

S.S. Rana & Co. Advocates
Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions